
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2765253/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment. Cancer Research, 2022, 82, 264-277.	0.4	8
2	Management of partial and nonâ€responding cutaneous squamous cell carcinoma. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 29-34.	1.3	2
3	Checkpoint immunotherapy of cutaneous squamous cell carcinoma in patients suffering from chronic lymphocytic leukaemia: divergent outcomes in two men treated with PDâ€I inhibitors. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 41-44.	1.3	1
4	Persister state-directed transitioning and vulnerability in melanoma. Nature Communications, 2022, 13, .	5.8	20
5	The predictive and prognostic significance of cellâ€free DNA concentration in melanoma. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 387-395.	1.3	17
6	Integrative Genomic Analyses of Patient-Matched Intracranial and Extracranial Metastases Reveal a Novel Brain-Specific Landscape of Genetic Variants in Driver Genes of Malignant Melanoma. Cancers, 2021, 13, 731.	1.7	12
7	Leptomeningeal disease from melanoma—Poor prognosis despite new therapeutic modalities. European Journal of Cancer, 2021, 148, 395-404.	1.3	16
8	Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib. Clinical Cancer Research, 2021, 27, 4500-4510.	3.2	8
9	Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases. European Journal of Cancer, 2021, 152, 139-154.	1.3	13
10	Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition – Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 Immunohistochemistry. Frontiers in Oncology, 2021, 11, 725549.	1.3	6
11	Coronavirus disease 2019 vaccine mimics lymph node metastases in patients undergoing skin cancer follow-up: A monocentre study. European Journal of Cancer, 2021, 154, 167-174.	1.3	15
12	Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma. Frontiers in Oncology, 2021, 11, 741993.	1.3	9
13	Melanoma Differentiation Trajectories Determine Sensitivity toward Pre-Existing CD8+ Tumor-Infiltrating Lymphocytes. Journal of Investigative Dermatology, 2021, 141, 2480-2489.	0.3	7
14	Fatal swelling of the groin – Clear cell sarcoma: a rare but important differential diagnosis to malignant melanoma. JDDG - Journal of the German Society of Dermatology, 2020, 18, 1165-1168.	0.4	2
15	Efficacy of cold atmospheric plasma vs. diclofenac 3% gel in patients with actinic keratoses: a prospective, randomized and raterâ€blinded study (ACTICAP). Journal of the European Academy of Dermatology and Venereology, 2020, 34, e844-e846.	1.3	10
16	Plasma Next Generation Sequencing and Droplet Digital-qPCR-Based Quantification of Circulating Cell-Free RNA for Noninvasive Early Detection of Cancer. Cancers, 2020, 12, 353.	1.7	24
17	Zelkovamycin is an OXPHOS Inhibitory Member of the Argyrin Natural Product Family. Chemistry - A European Journal, 2020, 26, 8524-8531.	1.7	5
18	Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis. European Journal of Cancer, 2020, 131, 18-26.	1.3	50

#	Article	IF	CITATIONS
19	Clinical and genetic analysis of melanomas arising in acral sites. European Journal of Cancer, 2019, 119, 66-76.	1.3	34
20	Targeting the H3K4 Demethylase KDM5B Reprograms the Metabolome and Phenotype of Melanoma Cells. Journal of Investigative Dermatology, 2019, 139, 2506-2516.e10.	0.3	27
21	Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV600E inhibition in melanoma. European Journal of Cancer, 2019, 109, 137-153.	1.3	20
22	Application of Circulating Cell-Free Tumor DNA Profiles for Therapeutic Monitoring and Outcome Prediction in Genetically Heterogeneous Metastatic Melanoma. JCO Precision Oncology, 2019, 3, 1-10.	1.5	25
23	Actinic keratoses treated with cold atmospheric plasma. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e37-e39.	1.3	41
24	Melanoma. Lancet, The, 2018, 392, 971-984.	6.3	1,016
25	RNA-seq analysis identifies different transcriptomic types and developmental trajectories of primary melanomas. Oncogene, 2018, 37, 6136-6151.	2.6	91
26	Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho. Clinical Cancer Research, 2017, 23, 3181-3190.	3.2	30
27	Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma. European Journal of Cancer, 2017, 81, 36-44.	1.3	76
28	Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma. European Journal of Cancer, 2017, 83, 142-145.	1.3	4
29	A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. Cell Reports, 2017, 21, 1953-1967.	2.9	117
30	Immunotherapy in melanoma: Recent advances and future directions. European Journal of Surgical Oncology, 2017, 43, 604-611.	0.5	216
31	Trametinib-Induced Remission of an <i>MEK1</i> -Mutated Langerhans Cell Histiocytosis. JCO Precision Oncology, 2017, 1, 1-5.	1.5	11
32	Targeted next generation sequencing of mucosal melanomas identifies frequent <i>NF1</i> and <i>RAS</i> mutations. Oncotarget, 2017, 8, 40683-40692.	0.8	69
33	The role of Orai–STIM calcium channels in melanocytes and melanoma. Journal of Physiology, 2016, 594, 2825-2835.	1.3	29
34	Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma. European Journal of Cancer, 2016, 59, 109-112.	1.3	45
35	JARID1B Enables Transit between Distinct States of the Stem-like Cell Population in Oral Cancers. Cancer Research, 2016, 76, 5538-5549.	0.4	46
36	Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient. European Journal of Cancer, 2016, 67, 66-72.	1.3	90

#	Article	IF	CITATIONS
37	Patients with pyoderma gangrenosum – analyses of the German <scp>DRG</scp> data from 2012. International Wound Journal, 2016, 13, 951-956.	1.3	21
38	Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency. Cancer Research, 2016, 76, 4347-4358.	0.4	63
39	Aetiology, comorbidities and cofactors of chronic leg ulcers: retrospective evaluation of 1 000 patients from 10 specialised dermatological wound care centers in Germany. International Wound Journal, 2016, 13, 821-828.	1.3	70
40	Mitochondrial oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma cell subpopulations. Experimental Dermatology, 2015, 24, 155-157.	1.4	41
41	Tumorstammzellen im Melanom. JDDG - Journal of the German Society of Dermatology, 2015, 13, 118-124.	0.4	0
42	Metastatic status of sentinel lymph nodes in melanoma determined noninvasively with multispectral optoacoustic imaging. Science Translational Medicine, 2015, 7, 317ra199.	5.8	239
43	Melanoma stem cells. JDDG - Journal of the German Society of Dermatology, 2015, 13, 118-124.	0.4	9
44	Combining <scp>BRAF^V</scp> ^{600E} inhibition with modulators of the mitochondrial bioenergy metabolism to overcome drug resistance in metastatic melanoma. Experimental Dermatology, 2015, 24, 709-710.	1.4	19
45	Melanoma. Nature Reviews Disease Primers, 2015, 1, 15003.	18.1	417
46	Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma. Oncogene, 2015, 34, 2951-2957.	2.6	99
47	SECTM1 Produced by Tumor Cells Attracts Human Monocytes via CD7-Mediated Activation of the PI3K Pathway. Journal of Investigative Dermatology, 2014, 134, 1108-1118.	0.3	24
48	Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells. Cancer Cell, 2013, 23, 811-825.	7.7	553
49	Transcriptional Profiling of Human Endogenous Retrovirus Group HERV-K(HML-2) Loci in Melanoma. Genome Biology and Evolution, 2013, 5, 307-328.	1.1	94
50	Targeting hyperactivation of the <scp>AKT</scp> survival pathway to overcome therapy resistance of melanoma brain metastases. Cancer Medicine, 2013, 2, 76-85.	1.3	126
51	Cancer stem cell definitions and terminology: the devil is in the details. Nature Reviews Cancer, 2012, 12, 767-775.	12.8	599
52	Identification of new genes associated with melanoma. Experimental Dermatology, 2011, 20, 502-507.	1.4	37
53	In vivo and ex vivo MR imaging of slowly cycling melanoma cells. Magnetic Resonance in Medicine, 2011, 66, 1362-1373.	1.9	9
54	From Cancer Stem Cells to Tumor Maintenance in Melanoma. Journal of Investigative Dermatology, 2011, 131, 1600-1604.	0.3	33

#	Article	IF	CITATIONS
55	Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population. Oncogene, 2010, 29, 6115-6124.	2.6	83
56	A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth. Cell, 2010, 141, 583-594.	13.5	1,052
57	RBP2â€H1/JARID1B is a transcriptional regulator with a tumor suppressive potential in melanoma cells. International Journal of Cancer, 2008, 122, 1047-1057.	2.3	69
58	Outcome survey of insect venom allergic patients with venom immunotherapy in a rural population. JDDG - Journal of the German Society of Dermatology, 2008, 6, 292-297.	0.4	7
59	Bowen's Disease on Porokeratotic Eccrine Ostial and Dermal Duct Nevus. Dermatologic Surgery, 2007, 33, 496-499.	0.4	27
60	Congenital Cartilaginous Rests of the Neck (Wattles). Dermatologic Surgery, 2006, 31, 1349-1350.	0.4	9
61	Loss of dipeptidyl peptidase IV immunostaining discriminates malignant melanomas from deep penetrating nevi. Modern Pathology, 2006, 19, 1378-1385.	2.9	19
62	Re-Expression of the Retinoblastoma-Binding Protein 2-Homolog 1 Reveals Tumor-Suppressive Functions in Highly Metastatic Melanoma Cells. Journal of Investigative Dermatology, 2006, 126, 1850-1859.	0.3	41
63	Post-traumatic iatrogenic aggravation of eruptive collagenomas in a child. European Journal of Dermatology, 2006, 16, 196-7.	0.3	3
64	Dermatoscopy of "dysplastic nevi": a beacon in diagnostic darkness. European Journal of Dermatology, 2006, 16, 479-93.	0.3	37
65	Overexpression and hyperphosphorylation of retinoblastoma protein in the progression of malignant melanoma. Modern Pathology, 2005, 18, 565-572.	2.9	32
66	Retinoblastoma-binding protein 2-homolog 1: a retinoblastoma-binding protein downregulated in malignant melanomas. Modern Pathology, 2005, 18, 1249-1257.	2.9	76
67	Gene Expression Profile Changes between Melanoma Metastases and their Daughter Cell Lines: Implication for Vaccination Protocols. Journal of Investigative Dermatology, 2005, 124, 401-404.	0.3	17
68	Severe contact urticaria to guar gum included as gelling agent in a local anaesthetic. Contact Dermatitis, 2005, 52, 307-308.	0.8	23
69	Elimination of a Community-Acquired Methicillin-Resistant Staphylococcus aureus Infection in a Nurse With Atopic Dermatitis. Archives of Dermatology, 2005, 141, 1520-2.	1.7	10
70	Cloning and characterization of the human FCRL2 gene. Genomics, 2005, 85, 264-272.	1.3	27
71	Ephrin-B2 is differentially expressed in the intestinal epithelium in Crohn's disease and contributes to accelerated epithelial wound healingin vitro. World Journal of Gastroenterology, 2005, 11, 4024.	1.4	38
72	Ephrin-B reverse signaling induces expression of wound healing associated genes in IEC-6 intestinal epithelial cells. World Journal of Gastroenterology, 2005, 11, 4511.	1.4	33

#	Article	IF	CITATIONS
73	Discrimination of Melanocytic Tumors by cDNA Array Hybridization of Tissues Prepared by Laser Pressure Catapulting. Journal of Investigative Dermatology, 2004, 122, 361-368.	0.3	24
74	Dysplastischer melanozytïż½rer Nïż½vus. Hautarzt, 2003, 54, 871-885.	1.2	5
75	Computer assisted learning in medicine: a long-term evaluation of the †Practical Training Programme Dermatology 2000'. Informatics for Health and Social Care, 2003, 28, 147-159.	1.0	19
76	Discrimination between gene expression patterns in the invasive margin and the tumour core of malignant melanomas. Melanoma Research, 2003, 13, 503-509.	0.6	39